Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Third time lucky for Roche in MAGE-A4?
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Familiar targets with a twist
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.
